Danish pharmaceutical company Novo Nordisk has announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with Type 1 and type 2 diabetes.
It becomes the second drugmaker to do so, following Eli Lilly’s announcement earlier this month that it was capping out-of-pocket costs to $35 a month for insulin.
